Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis

The analyses of detailed structure characterized by TEM and DLS confirmed the nano-size of the particle 10-20 nm and FTIR confirmed for antileishmanial drug encapsulation in to PLGA-PEG. The dose of miltefosine is decreased by fifty percent as the IC50 value is decreased from 0.2 to 0.1 μg. Further inhibitions of amastigotes in the splenic tissue with these nanoparticles are significantly more than the conventional miltefosine and PLGA-PEG encapsulated Amphoterecin B (23.21 ± 23/89.09 ± 52.7/92.12 ± 55.1).63